Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Pyruvate kinase M2 isozyme (PKM2)

In vitro and cell culture studies suggest PKM2 activators could help treat cancers with low tumor serine levels. High throughput screening and hit optimization identified mid-nanomolar activators of the cancer-associated glycolytic enzyme PKM2. In a human lung cancer cell line, a PKM2 activator inhibited proliferation only when serine was absent from the culture media, supporting a link between cancer cell glycolysis and serine biosynthesis. Next steps could include identifying cancer cell lines that are highly sensitive to PKM2 activators due to alterations in the serine biosynthetic pathway.
Agios Pharmaceuticals Inc. has a discovery-stage program targeting PKM2 in cancer.
Dynamix Pharmaceuticals Ltd.'s PKM2 activator, DNX-3000, is in preclinical development in cancer.

SciBX 5(42); doi:10.1038/scibx.2012.1105
Published online Oct. 25, 2012

Patent and licensing status undisclosed

Kung, C. et al. Chem. Biol.; published online Sept. 21, 2012;
doi:10.1016/j.chembiol.2012.07.021
Contact: Lenny Dang, Agios Pharmaceuticals Inc., Cambridge, Mass.
e-mail:

lenny.dang@agios.com